Abstract
Efficacy and safety are crucial considerations in judging drugs, for example, whether or not to include them in a local formulary. More and more, pharmacoeconomic aspects are becoming of additional importance. How should we interpret such pharmacoeconomic studies? To enhance accurate interpretation of such studies among our readership, we present the basic concepts of pharmacoeconomics in this commentary.
This Commentary was previously published in Dutch as part of a paper by M.J. Postma, W.J.M.J. Rutten, C.S. de Vries (Pharmaceutisch Weekblad 2001; 41: 1542–5)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJW et al. Economic evaluation of influenza vaccination; assessment for the Netherlands. PharmacoEconomics 1999; 16: 33–40.
Postma MJ, van den Hoek JAR, Beck EJ, Heeg BMS, Jager JC, Coutinho RA et al. Farmaco-economische evaluatie van universele HIV-screening in de zwangerschap; een kosten-effectiviteitsanalyse voor Amsterdam. Ned Tijdschr Geneeskd 2000; 144: 749–54.
Postma MJ, Bakker A, Welte R, van Bergen JEAM, van den Hoek JAR, de Jong-van den Berg LTW, Jager JC. Screening op asymptomatische infectie met Chlamydia trachomatis in de zwangerschap; gunstige kosteneffectiviteit bij een prevalentie van tenminste 3%. Ned Tijdschr Geneeskd 2000; 144: 2350–4.
College voor Zorgverzekeringen (CvZ). Richtlijnen voor Farmaco-economisch Onderzoek. Amstelveen, The Netherlands: CvZ 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Postma, M.J. Pharmacoeconomic research. Pharm World Sci 25, 245–246 (2003). https://doi.org/10.1023/B:PHAR.0000006525.10662.50
Issue Date:
DOI: https://doi.org/10.1023/B:PHAR.0000006525.10662.50